Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

@article{AbuKhalaf2006LongtermAO,
  title={Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer},
  author={Maysa Abu-Khalaf and Vinni Juneja and Gina G. Chung and Michael P DiGiovanna and Rebecca L Sipples and Meghan L McGurk and Daniel Zelterman and Bruce G. Haffty and Michael Reiss and Frans J. Th. Wackers and Forrester A. Lee and Barbara Burtness},
  journal={Breast Cancer Research and Treatment},
  year={2006},
  volume={104},
  pages={341-349}
}
This study evaluated the incidence of late cardiotoxicity after dose-dense and -intense adjuvant sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) for breast cancer (BC) with ≥ 4 involved ipsilateral axillary lymph nodes. Patients were enrolled from 1994 to 2001 after definitive BC surgery if ≥4 axillary nodes were involved. Planned treatment was A 90 mg/m2 q 14 days × 3, T 250 mg/m2 q 14 days × 3, C 3 g/m2 q 14 days × 3 with filgrastim (G) support. Left ventricular ejection… CONTINUE READING